QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review - PubMed (original) (raw)

QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review

Lior Jankelson et al. Heart Rhythm. 2020 Sep.

Abstract

Chloroquine and hydroxychloroquine are now being widely used for treatment of COVID-19. Both medications prolong the QT interval and accordingly may put patients at increased risk for torsades de pointes and sudden death. Published guidance documents vary in their recommendations for monitoring and managing these potential adverse effects. Accordingly, we set out to conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine. We searched on MEDLINE and Embase, as well as in the gray literature up to April 17, 2020, for the risk of QT prolongation, torsades, ventricular arrhythmia, and sudden death with short-term chloroquine and hydroxychloroquine usage. This search resulted in 390 unique records, of which 41 were ultimately selected for qualitative synthesis and which included data on 1515 COVID-19 patients. Approximately 10% of COVID-19 patients treated with these drugs developed QT prolongation. We found evidence of ventricular arrhythmia in 2 COVID-19 patients from a group of 28 treated with high-dose chloroquine. Limitations of these results are unclear follow-up and possible publication/reporting bias, but there is compelling evidence that chloroquine and hydroxychloroquine induce significant QT-interval prolongation and potentially increase the risk of arrhythmia. Daily electrocardiographic monitoring and other risk mitigation strategies should be considered in order to prevent possible harms from what is currently an unproven therapy.

Keywords: Arrhythmia; COVID-19; Chloroquine; Coronavirus; Hydroxychloroquine; SARS-CoV-2; Sudden death; Torsades de pointes.

PubMed Disclaimer

Figures

Figure 1

Flowchart of study screening and selection.

Cited by

Prolonged QT Interval in SARS-CoV-2 Infection: Prevalence and Prognosis.
Farré N, Mojón D, Llagostera M, Belarte-Tornero LC, Calvo-Fernández A, Vallés E, Negrete A, García-Guimaraes M, Bartolomé Y, Fernández C, García-Duran AB, Marrugat J, Vaquerizo B. Farré N, et al. J Clin Med. 2020 Aug 21;9(9):2712. doi: 10.3390/jcm9092712. J Clin Med. 2020. PMID: 32839385 Free PMC article.
Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
Izcovich A, Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Kum E, Qasim A, Khamis AM, Rochwerg B, Agoritsas T, Chu DK, McLeod SL, Mustafa RA, Vandvik P, Brignardello-Petersen R. Izcovich A, et al. BMJ Open. 2022 Mar 2;12(3):e048502. doi: 10.1136/bmjopen-2020-048502. BMJ Open. 2022. PMID: 35236729 Free PMC article.
Adverse Cardiovascular Effects of Anti-COVID-19 Drugs.
Liu D, Zeng X, Ding Z, Lv F, Mehta JL, Wang X. Liu D, et al. Front Pharmacol. 2021 Aug 25;12:699949. doi: 10.3389/fphar.2021.699949. eCollection 2021. Front Pharmacol. 2021. PMID: 34512335 Free PMC article. Review.
COVID-19-Associated Cardiovascular Complications.
Lee CCE, Ali K, Connell D, Mordi IR, George J, Lang EM, Lang CC. Lee CCE, et al. Diseases. 2021 Jun 29;9(3):47. doi: 10.3390/diseases9030047. Diseases. 2021. PMID: 34209705 Free PMC article. Review.
QTc interval prolongation, inflammation, and mortality in patients with COVID-19.
Gulletta S, Della Bella P, Pannone L, Falasconi G, Cianfanelli L, Altizio S, Cinel E, Da Prat V, Napolano A, D'Angelo G, Brugliera L, Agricola E, Landoni G, Tresoldi M, Rovere PQ, Ciceri F, Zangrillo A, Vergara P. Gulletta S, et al. J Interv Card Electrophysiol. 2022 Mar;63(2):441-448. doi: 10.1007/s10840-021-01033-8. Epub 2021 Jul 22. J Interv Card Electrophysiol. 2022. PMID: 34291390 Free PMC article.

References

1. Centers for Disease Control and Prevention Information for Clinicians on Therapeutic Options for Patients with COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html Available at:
1. Plaquenil (hydroxychloroquine sulfate). Product monograph. Sanofi-Aventis Canada Inc; Laval, Quebec, Canada: August 2019.
1. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–1022. - PubMed
1. Roden D.M. Predicting drug-induced QT prolongation and torsades de pointes. J Physiol. 2016;594:2459–2468. - PMC - PubMed
1. Kannankeril P., Roden D.M., Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62:760–781. - PMC - PubMed

QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review - PubMed (original) (raw)